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Background: Although there are no established biomarkers for posttraumatic stress disorder (PTSD) as yet,
biological investigations of PTSD have made progress identifying the pathophysiology of PTSD. Given the
biological and clinical complexity of PTSD, it is increasingly unlikely that a single biomarker of disease will be
identified. Rather, investigations will more likely identify different biomarkers that indicate the presence of
clinically significant PTSD symptoms, associate with risk for PTSD following trauma exposure, and predict or
identify recovery. While there has been much interest in PTSD biomarkers, there has been less discussion of
their potential clinical applications, and of the social, legal, and ethical implications of such biomarkers.
Objective: This article will discuss possible applications of PTSD biomarkers, including the social, legal, and
ethical implications of such biomarkers, with an emphasis on military applications.
Method: Literature on applications of PTSD biomarkers and on potential ethical and legal implications will
be reviewed.
Results: Biologically informed research findings hold promise for prevention, assessment, treatment planning,
and the development of prophylactic and treatment interventions. Aswith any biological indicatorof disorder,
there are potentially positive and negative clinical, social, legal, and ethical consequences of using such
biomarkers.
Conclusions: Potential clinical applications of PTSD biomarkers hold promise for clinicians, patients, and
employers. The search for biomarkers of PTSD should occur in tandem with an interdisciplinary discussion
regarding the potential implications of applying biological findings in clinical and employment settings.
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T
here has been extensive progress in characterizing
the biological basis of posttraumatic stress dis-
order (PTSD). Perturbations in the hypothalamic 
pituitary adrenal (HPA) axis, sympathetic adrenomedullary
system, and alterations in brain structure and function
have been associated with risk for development of PTSD
following trauma exposure, with PTSD symptoms and
diagnosis, and with recovery (e.g., Pitman et al., 2012;
Schmidt, Kaltwasser, & Wotjak, 2013). In a new era of
‘‘big’’ data that allows for examination and detection of
genome-wide genomics, transcriptomics, proteomics, and
metabolomics in conjunction with brain imaging data,
there is seemingly endless opportunity for new discovery.
As the field moves closer to identifying biomarkers based
on established criteria, it is important to anticipate how
such markers would be used (Yehuda, Neylan, Flory,
& McFarlane, 2013). These questions are particularly
relevant for the military (prevention) and the Veteran’s
Administration (treatment), which represent institutions
in a position to take leadership in this arena.
Although many biological alterations have been ob-
served in association with PTSD, no current biological
variable has yet passed the threshold for a reliable and
specific PTSD biomarker (for recent reviews of potential
biomarkers of PTSD, see Baker, Nievergelt, & O’Connor,
2012; Bomyea, Risbrough, & Lang, 2012; DiGangi et al.,
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A disease biomarker refers to ‘‘a characteristic that is
objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or
pharmacological responses to a therapeutic intervention’’
(Biomarkers Definitions Working Group, 2001). It may
be that both etiologically and phenotypically PTSD does
not represent a single construct, and that this complexity
has confounded efforts to identify robust biomarkers.
However, the potential of advanced computational and
multisystemic approaches to identify the influence of
multiple relevant networks may lead to important break-
throughs. Increasingly, a systems biology approach that
takes advantage of innovations in integrative and compu-
tational biology is being pursued in order to characterize
the complex interplay of multiple biological levels (mole-
cular, cellular, etc.) with environmental and psychological
stimuli. Extant biological research on PTSD suggests that
information obtained from anygiven system or dimension
of data alone may yield a biomarker relating to some
aspect of PTSD, but that a comprehensive understanding
of this condition may only be obtained from evaluating
entirebiological networks that in turn increase ordecrease
the risk of illness or affect illness severity. Thus, PTSD
symptoms may be best conceptualized as emergent pro-
perties of complex networks, as opposed to corebiological
processes associated with a disease driven by a small
number of genes. Such a multifaceted and dynamic con-
ceptualization of PTSD risk and illness networks or
pathways may require a shift away from a more narrowly
defined ‘‘biomarker’’ of PTSD, and imply the need for
more nuanced interpretations and clinical applications of
identified PTSD networks. Regardless, the identification
of biological systems associated with risk and disorder
holds promise for the development of diagnostic tests,
prognostic indicators, and prophylactic and treatment
interventions, and such biological research in PTSD has
been supported by stakeholders such as the U.S. Depart-
ments of Defense andVeteran’s Affairswith aneye toward
translational applications.
Biological measures of PTSD should reflect predictive
markers of risk/resilience (pre- or posttrauma exposure),
or disease markers indicating diagnostic status or symp-
tom severity. Morerefined applications include prognostic
markers of therapy response that may inform treatment
choice or monitor response (Schmidt et al., 2013). Once
the biological correlates of these constructs are identified,
such biomarkers may help identify those at highest risk
following trauma exposure, target prevention efforts, aid
in diagnosis, treatment planning, and recovery assessment
forpatients,andultimatelyinformthedevelopmentofsafe
and effective pharmacological treatments for PTSD. This
article will review the possible applications and implica-
tions of PTSD biomarkers, with an emphasis on military
applications (see Fig. 1 for a schematic overview). Despite
the significant interest in the identification of biomarkers
of PTSD, there has been relatively little discussion in the
literature regarding the potential uses of such biomarkers
or the social, ethical, or legal implications of psychiatric
biomarkers in general, and PTSD in particular (Lakhan,
Vieira, & Hamlat, 2010; Singh & Rose, 2009).
Biomarkers of PTSD symptoms or diagnosis
A biomarker that objectively confirms PTSD diagnosis
and/or symptom severity should be applicable in clinical,
forensic, and disability/compensation contexts or in any
setting where there may be a need to verify symptoms.
Theseincludecontextswherepatientsmaydeny,minimize,
or exaggerate symptoms, have difficulty describing symp-
toms, or have difficulty attributing symptoms to trauma
exposure. For example, there may be significant conse-
quences of a positive PTSD diagnosis for disability and
compensation entitlements, which may influence over-
reporting of symptoms, whether consciously or not. In
other cases, service members may deny or minimize
symptoms out of concerns over duty assignments and
promotion both during military service and following
discharge for veterans seeking employment in law enforce-
ment, security, or other occupations involved in public
safetyandcrisisresponse.AdmittingthepresenceofPTSD
symptoms such as extreme irritability and angryoutbursts
or suicidality could affect employment in work that
requires carrying a weapon, for example. The presence of
PTSD may also be used as a mitigating influence in court
casesinvolvingviolentoraggressivebehavior,orsubstance
abuse related problems (such as driving while drunk),
both of which are common among service members with
PTSD. Indeed, PTSD is one of the most litigated mental
disorders in civilian settings (Bottalico & Bruni, 2012).
Accurate diagnosis is also essential for treatment
planning. A biomarker of PTSD may be useful as an
adjunct to clinical interview, just as lab tests are informa-
tiveinmedicine.Whilemostclinicianscanaccuratelydiag-
nose PTSD in patients with clear trauma exposure and
willingness toreportsymptoms,differentialdiagnosiswith
PTSD can be challenging, especially in the context of
comorbid diagnoses, mild traumatic brain injury (TBI),
potentially overlapping symptoms (e.g., irritability, anhe-
donia, sleep problems, problems with concentration,
suicidality, interpersonal and relationship problems), and
complicated lifecourse trajectories and stressors. The
degree of symptom overlap and comorbidity between
PTSD and other common sequelae of trauma such as
major depressive disorder (MDD) poses challenges to
reliable diagnosis. Epidemiological studies consistently
show that 75 88% of adults and adolescents with PTSD
meet criteria for at least one other psychiatric disorder,
most often major depression (Brady, Killeen, Brewerton,
& Lucerini, 2000; Breslau, Davis, Andreski, & Peterson,
1991; Creamer, Burgess, & McFarlane, 2001; Kessler,
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et al., 2003). There is now an unprecedented number of
veterans of the wars in Iraq and Afghanistan who present
for diagnosis and treatment with histories of co-occurring
trauma and blast injury exposures, estimated at 12 23%
(Hoge et al., 2008; Schneiderman, Braver, & Kang, 2008;
Terrio et al., 2009).
An objective lab test for PTSD could also reduce the
stigma associated with a PTSD diagnosis, which creates
a barrier to help-seeking and causes additional suffering
for patients and families. This may be especially relevant
in cultures in which any mental health problems could be
perceived as signs of weakness or shame, such as military
and ethnic minority communities. For example, among
military personnel and veterans, the absence of objective
validation of PTSD as a legitimate war-related injury can
fuel the perception that PTSD and other deployment-
related mental injuries are not ‘‘real.’’ The fact that not all
warfighters develop PTSD can lead tomisperceptions that
such symptoms are not about the battlefield, but reflect
constitutional weakness best overcome with mental dis-
cipline rather than mental health treatment. This stigma
can create a divide between soldiers and the social support
networkscrucialtotheirrecovery.Alternatively,somemay
interpret the presence of a biomarker of PTSD to mean
that a potentially temporary injury will never heal.
Biomarkers as predictors or risk factors for
PTSD
Some biomarkers may be indicative of current psycho-
pathology (i.e., a state marker), whereas others may reflect
pre-traumatic risk. It is also useful to distinguish pre-
traumatic from posttraumatic markers of risk. Both types
havepotentialapplicationsforsecondarypreventionefforts.
Secondary, or ‘‘indicated,’’ prevention is a public health
approach that focuses specifically on a population known
to be at risk of developing a condition or disorder. Iden-
tification of pre-trauma risk markers (e.g., prior trauma
exposure, personality traits, gene expression patterns,
neurological structure) might lead to the development of
programs that minimize the chance of exposure, or that
focus early intervention resources on higher risk indivi-
duals following trauma exposure, whereas post-exposure
riskmarkers(e.g.,dynamicchangesreflectingneurological
adaptation after trauma) would suggest immediate inter-
vention or monitoring (i.e., ‘‘watchful waiting’’).
Fig. 1. Schematic representation of potential applications of PTSD biomarkers.
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through which risk is conferred might also inform the de-
velopment of prevention efforts targeting those pathways
through environmental or pharmacologic interventions.
For example, low cortisol levels in the immediate after-
math of trauma have been found to predict the develop-
ment of PTSD (Delahanty, Nugent, Christopher, &
Walsh, 2005; Delahanty, Raimonde, & Spoonster, 2000;
Yehuda, McFarlane, & Shalev, 1998) as have pre-exposure
dysregulationsalong theglucocorticoid signaling pathway
(Van Zuiden, Kavelaars, Geuze, Olff, & Heijnen, 2013).
Should the literature support such findings, pharmacolo-
gic interventions that regulate cortisol or influence the
HPA axis may ultimately be developed as prophylactic
measures (Delahanty et al., 2013; Yehuda & Golier, 2009).
Indeed, Zohar et al. (2011) report a reduced risk for the
development of PTSD among patients who received a
single, high dose of hydrocortisone within 6 hours of a
traumatic event. Cognitive and/or behavioral interven-
tions might also be developed that re-regulate disordered
neuroendocrine markers, or that function to counteract
the risk conferred by the dysregulation of the HPA
axis. Cognitive and/or behavioral correlates of such
neuroendocrine risk factors might also be identified and
targeted.
Biomarkers to validate exposure
In certain circumstances, it may be useful to have access to
biomarkers related to trauma exposure rather than to the
development of PTSD. Certainly, the majority of patients
are able to accurately report their history of trauma
exposure for purposes of diagnosis, case formulation and
treatment planning. However, in cases when it is difficult
toestablishtraumaexposure,orwhentheexposureitselfis
contested, abiologic markerof trauma exposure may have
clinical utility. For example, children exposed to trauma,
particularly abuse at the hands of a parent or guardian,
may be unable or unwilling to disclose that information.
Ofcourse,aneurobiologicalmarkerthatidentifiedtrauma
exposurewould not replace the need for clinical sensitivity
regarding the undisclosed issue, but an awareness of the
potential role of trauma in the etiology of the present-
ing problem may nonetheless be helpful for a clinician.
Individuals with a stake in documenting their trauma
exposure(e.g., a rapevictim, abatteredwoman involvedin
a contentious legal case) could also potentially benefit
from an objective marker of traumatization.
Although this is conceptually a straightforward cate-
gory, an important feature of the stress response system
is that most biological changes resulting from psycholo-
gical trauma exposure are transient. Thus, unless there are
clear demonstrations of chronic and enduring manifesta-
tions, biomarkers of exposuremay not be possible. A large
meta-analysis of cross-sectional data found that trauma-
exposed individuals demonstrated enhanced negative HPA
axis feedback comparable to those with PTSD (Morris,
Compas, & Garber, 2012). However, trauma-exposed per-
sons had morning cortisol levels and daily cortisol out-
put similar to trauma-unexposed controls. Hair cortisol
has also been investigated as a potential biomarker of
trauma exposure. For example, trauma-exposed indivi-
dualswith andwithout PTSD had lower hair cortisol con-
centrations than healthy, unexposed individuals (Steudte
et al., 2013). Recent research in epigenetics has shown
enduring molecular changes in response to early life
adversity, but a biomarker reflecting such changes would
still be difficult to definitively link with a specific event.
Furthermore, a biomarker of exposure should be able to
distinguish the effects of trauma exposure from the long-
term alterations associated with chronic or severe stress
(Miller, 2008).
Predictors of recovery and verification of
recovery/remission
Neurobiological studies of PTSD might identify biomar-
kers that predict treatment response, a clinical application
of significant utility. Such biomarkers might be used to
predict response to treatment, or to different types of
treatment (i.e., a moderator), as well as to monitor treat-
ment response. Given the time- and resource-intensive
nature of exposure therapies for PTSD, and since not
all patients will recover from these treatments, the ability
to predict which patients are likely to respond to any (or
specific) treatments could facilitate treatment planning
and optimize resource allocation. For example, prelimin-
ary data show that cytosine methylation and expression
of the GR gene at pre-treatment predicted PTSD status
following Prolonged Exposure therapy (Yehuda, Daska-
lakis, et al., 2013). Imaging studies have also shown that
larger anterior cingulate cortex volume, decreased right
amygdala activity, and increased anterior cortex activity
associate with better response to cognitive behavioral
therapy, whereas LL 5HTTLPR genotype, BDNF serum
levels, and differential conditioned fear response associate
with better SSRI/SNRI response (Schmidt et al., 2013).
Such stratification markers might lead to improved
clinical and economic outcomes. Biological measures
should be added to treatment trials to further examine
predictors of treatment response and elucidate underlying
mechanisms of pathophysiology.
Biomarkers of treatment response (or risk) may also
have utility not only in guiding the clinician’s treatment
choice,buttheymayalsoinfluencepatientbehavior(Perlis,
2011). Patients known to be at risk for PTSD may be more
likely to recognize early signs of disorder and to seek help.
Predictive and prognostic indicators may also increase
treatment adherence, enhancing motivation to remain in
even difficult therapies, such as those involving exposure
topainfulmemoriesoranxiety-producingsituations.Prog-
nostic indicators may also help patients set realistic goals
Amy Lehrner and Rachel Yehuda
4
(page number not for citation purpose)
Citation: European Journal of Psychotraumatology 2014, 5: 23797 - http://dx.doi.org/10.3402/ejpt.v5.23797and to plan for the future. The riskof such markers is that
indicators of poor prognosis or treatment response may
contribute to increased drop-out and decreased treatment
adherence, becoming self-fulfilling prophesies.
Consensus regarding the definition of recovery (or
meaningful improvement) and assessment of recovery
status is important for rigorous evaluations of PTSD
therapies and for clinical decision-making regarding on-
going treatment planning. However, the treatment out-
come literature has yet to coalesce around a universally
accepted, objective measure of recovery from PTSD. As
a result, ‘‘recovery’’ is often defined differently across
studies. In its review of the PTSD treatment literature, the
Institute of Medicine (IOM) Committee on Treatment
of Posttraumatic Stress Disorder (2008) identified incon-
sistencies in defining and assessing recovery as a critical
problemintheliterature.Furthercomplicatingassessment
of recovery are findings that patient self-report and clini-
cianratingsmaynotnecessarilycorrelate,orthattherecan
be recovery in one domain but not another. A biomarker
of recovery could significantly inform the determination
of recovery status. For example, neurobiological research
hasidentifiedpsychotherapy-relatedchangesinthehippo-
campus and hypothalamus at posttreatment (Barsaglini,
Sartori, Benetti, Pettersson-Yeo, & Mechelli, 2014).
A recovery biomarker might also contribute to our
understanding of the underlying mechanisms of the dis-
ease and recovery processes (which themselves might be
targeted for intervention). A recovery biomarker may as-
sociate with state (i.e., may be altered at baseline as well),
or it may emerge posttreatment. In the first case, it reflects
a normalization of biological systems that were altered in
association with PTSD, in the second it may reflect the
recruitment of other systems or brain regions to compen-
sate for PTSD-related impairments (Mechelli, 2010).
A number of studies have used neuroendocrine measures
of treatment response and provided some proof of
concept. For example, Olff, De Vries, Guzelcan, Assies,
and Gersons (2007) found an increase in dehydroepian-
drosterone (DHEA) levels among those who responded to
treatment for PTSD. Another study found that non-
responders to treatment for PTSD resulting from the
9/11 World Trade Center terrorist attacks had significant
declines in posttreatment cortisol levels that distinguished
them from responders (Yehuda et al., 2009). A case study
of a female PTSD patient reported an increase in basal
cortisollevelsandmoreattenuatedcortisolsuppressionon
the dexamethasone suppression test in association with
symptom reduction following EMDR treatment (Heber,
Kellner, & Yehuda, 2002). Recently, a pilot study of
combat veterans treatedwith Prolonged Exposuretherapy
found decreased methylation of the FKBP5 gene (FKBP51)
exon 1 promoter region in association with recovery
(Yehuda, Daskalakis, et al., 2013).
Subtyping of PTSD
Biomarkers of PTSD have the potential to inform debates
regarding subtypes of PTSD, potentially identifying dis-
tinct biological signatures with implications for diagnosis,
treatmentplanninganddevelopmentofnewinterventions.
For example, the construct of complex PTSD (also called
Disorders of Extreme Stress Not Otherwise Specified,
or DESNOS), has been researched and reported in the
literature, but is not codified in the DSM or the ICD,
and remains a subject of debate (e.g., Cloitre, Garvert,
Brewin, Bryant, & Maercker, 2013; Ford, 1999; Friedman,
Resick, Bryant, & Brewin, 2011; Van der Kolk, Roth,
Pelcovitz, Sunday, & Spinazzola, 2005). Proponents argue
that complex PTSD results from prolonged and repeated
interpersonal trauma, usually experienced in childhood,
characterized by a loss of control and absence of a means
of escape (e.g., Herman, 1992). These forms of trauma
may induce sequelae that are distinct from those resulting
from single-episode or more circumscribed trauma (e.g.,
car accident or rape), such as a more diffuse and complex
symptom presentation, characterological disturbances in
interpersonal relatedness and self-concept, dissociation,
affective dysregulation, and patterns of self-harm includ-
ing self-injurious behavior and vulnerability to repeated
abuse (Cloitre et al., 2013; Pelcovitz et al., 1997). Those
who argue for the validity of the construct argue that
patients with complex PTSD require specialized trauma-
focused treatment, and that conventional treatments for
PTSD may have poorer outcomes or at worst have iat-
rogenic effects for these patients (Ford & Kidd, 1998; Van
der Kolk, 2002).
In addition to complex PTSD, personality-based
PTSD subtypes along the internalizing/externalizing di-
mensionhavebeenproposedbasedonlatentclassanalyses
(Dalenberg, Glaser, & Alhassoon, 2012). Those in the
internalizing class have higher levels of comorbid anxiety
and depression, whereas those in the externalizing class
have more significant problems with anger, aggression,
and substance abuse (Forbes, Elhai, Miller, & Creamer,
2010; Wolf et al., 2012). While biological studies of these
subtypes have been limited, analyses of their genetic
structures using twin data from Vietnam-eraveterans have
found different genetic risk factors for the internalizing/
externalizing dimensions, as well as a common genetic
factor that increases risk for comorbidity across dimen-
sions (Wolf et al., 2010).
Clinicians have also observed that certain patients with
PTSD present primarily with anxiety and fear responses
(consistent with theories of the development, mainte-
nance, and treatment of PTSD), while others present with
primary emotions such as anger, guilt, or shame. These
clinical presentations may simply reflect different pheno-
types of a single, underlying PTSD construct, or they may
be better understood as subtypes or as distinct clinical
phenomena. Finally, the research literature is inconclusive
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enon across different populations, such as civilian rape
survivors and combat veterans (IOM, 2008). It is un-
known whether heterogeneity in the nature and chronicity
of the traumatic stressors and in potentially relevant
population characteristics such as age, race, ethnicity,
sex,education,andveterancohortleadstodifferentPTSD
subgroups.
Highlighting the relevance of biological markers to
inform psychiatric nosology, such research supported the
reclassification of PTSD in DSM-V (American Psychia-
tric Association, 2013) from the anxietydisorders to a new
classification, ‘‘Trauma- and Stressor-Related Disorders.’’
Biological findings indicating that the dissociative subtype
of PTSD may represent different biological processes
(Lanius et al., 2010; Mickleborough et al., 2011) also
informed the addition of a dissociative specifier to the
DSM-V PTSD diagnosis.
Challenges in identifying biomarkers of PTSD
There are many challenges to the identification of valid,
reliable PTSD biomarkers. Although many biological
abnormalities have been associated with PTSD, including
HPA axis and neurobiological alterations, there is sig-
nificant heterogeneity in the literature (e.g., Zoladz
& Diamond, 2013). PTSD is a multifaceted psychological
disorder with symptoms across four clusters and multiple
longitudinal trajectories (Bonanno et al., 2012), encom-
passing heterogeneous phenotypes. Furthermore, bio-
logical (genetic, epigenetic, endocrine, immunological,
neurological), environmental (nature and developmental
timing of trauma), psychological (cognitive, emotional,
behavioral), and social vulnerability factors likely interact
in complex ways to increase risk for PTSD. Given the
diagnostic heterogeneity of PTSD and its multifactorial
etiology, it is unlikely that a single biomarker will be iden-
tified (Schmidt et al., 2013; Zoladz & Diamond, 2013).
Furthermore, even if a marker or panel of markers was
reliably observed at a given level in people with PTSD,
an additional issue is whether the marker is unique to
PTSD (versus a markerof trauma exposure, TBI, orother
psychiatric disorder). Other challenges include whether
and how comorbidities such as depression and TBI,
the degree of symptom severity, or the degree of symp-
tom improvement over time affect the biological signal.
Finally, much researchonPTSD usesciviliansampleswho
have experienced a single traumatic event, such as an
accident or assault. For example, of the 11 PTSD studies
identified that incorporate brain imaging pre-and post-
psychotherapy, only one uses a military sample (Aupperle
et al., 2013; Bryant, Felmingham, Kemp, et al., 2008;
Bryant, Felmingham, Whitford, et al., 2008; Cisler et al.,
2014; Falconer, Allen, Felmingham, Williams, & Bryant,
2013; Farrow et al., 2005; Felmingham et al., 2007;
Lindauer et al., 2008; Peres et al., 2007, 2011; Roy et al.,
2010). This population may differ from the military popu-
lation both in terms of baseline demographic and psycho-
logicalcharacteristics(e.g.,age,gender,personality)andin
the types and chronicity of trauma they have experienced.
Biomarkers for use in the military must be validated in
military samples.
With the exception of strongly genetically deter-
mined medical or psychiatric disorders (e.g., Huntington’s
disease), biomarkers of disease reflect relative risk for
disorder (or recovery). The probabilistic nature of such
markers raises the question of the appropriate threshold
for establishing avalid and reliable biomarker. While there
are established frameworks for identifying and validating
novel biomarkers, the process of translation to clinical
applications requires consideration of accuracy, positive
and negative predictive values, and the receiver operating
characteristic (ROC) curve for any test (Fuzery, Levin,
Chan, & Chan, 2013; Perlis, 2011). As noted by Perlis
(2011), the criteria for the validity and utility of a test
depend on how it will be used, so that determining thresh-
olds for clinical utility a priori is ill-advised. The potential
utility of a putative biomarker depends on many con-
siderations, including the consequence of a false positive
or false negative on a test, or the potential of the bio-
marker to improve prediction or classification in conjunc-
tion with existing clinical indicators (Perlis, 2011). For
example, a highly accurate test may be informative in a
clinical context but inadequate in a legal one.
Clinical, ethical, social, and legal considerations
in the use of PTSD biomarkers
Whereas the above discussion highlights the numerous
areas in which a PTSD biomarker might have therapeutic,
social, and practical benefits for veterans, clinicians, and
institutions such as the military, it is incumbent on the
field to consider potentially detrimental outcomes as well.
Just as the identification of PTSD biomarkers may reduce
stigma and legitimize suffering for some, biomarkers of
disorder may increase stigma for others. The knowledge
that there is a biological basis to one’s expressed PTSD,
or that one is at high risk for disorder following trauma
exposure, may negatively affect self-identity and influence
social relationships by influencing others’ perceptions
(Singh & Rose, 2009). Military service members who
already feel unalterably damaged by their traumatic expe-
riences may register the presence of a biological indicator
of PTSD as a physical verification that they are ‘‘damaged
goods’’ and fundamentally different from others. Such
an interpretation could have the unintended consequence
of creating hopelessness and disinvestment in therapy
for those who believe they are permanently marked and
cannot be healed. Conversely, for those experiencing dis-
tressing and disabling symptoms, a ‘‘negative’’ result may
invalidate their suffering and potentially affect compensa-
tion claims. For warfighters steeped in a military culture
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sence of objective verification of disorder may lead to
rejection or judgment by superior officers, soldiers, and
even family.
Singh and Rose (2009) caution against the risk of
reductionist and oversimplistic understandings and appli-
cations of psychiatric illness biomarkers. It will be easy
for employers and lay people to overvalue an objective
biological marker, and the use of a test for a biomarker
of disorder must be accompanied by information and
education to all users of the test and to the public
regarding the probabilistic nature of such indicators. As
with any medical test, a test for a PTSD biomarker will
always have the risk of false positives and false negatives.
One can have prostate cancer with a normal PSA level,
for example. Conversely, the presence of the BRCA1 gene
does not signify the presence of breast cancer. As with
other forms of psychological assessment or testing, ethical
imperatives of testing for PTSD biomarkers include feed-
back about the nature of the test results and discussion
of the idiosyncratic meaning for the individual. Further-
more, it will be important not to oversimplify the disorder
itself and equate it with a single biological alteration. The
principle of equifinality suggests that there may be diverse
biological networks or systems implicated in PTSD.
Indeed, brain imaging research led to the recognition of
a dissociative subtype of PTSD with different phenotypic
and biological characteristics, as noted above (Lanius
et al., 2010).
With regard to biological markers of risk, the potential
misunderstanding and misapplication of such markers
is even greater given the probabilistic nature of such
indicators. It is unclear how screening for biomarkers of
risk will affect employment where riskof trauma exposure
is high, such as military, law enforcement, or emergency
response contexts. How much should the presence of risk
factors influence decisions about who should serve and in
what capacity, or whether those who experience a critical
incident should be returned to the battlefield or to work?
Since trauma exposure is a precondition for PTSD, and
since the costs of PTSD are high (both for the individual
and the organization), will employers choose to simply
screen out all candidates with risk markers, or will such
indicators inform job placement or lead to assignments
that reduce risk for exposure (such as non-combat or
desk-based jobs)? Using biomarkers to screen applica-
tions may protect the institution from long-term financial
costs associated with compensation claims, poor perfor-
mance, and potential legal liability. Such use may also
protect soldiers, their families, and the community from
the psychological and economic costs of PTSD, as well
as the consequences for public safety. On the other hand,
such screening restricts individual rights to employment
and service based on outcomes that may not occur. Fur-
thermore, mandatory screening raises questions of con-
sent and confidentiality (Caux, Roy, Guilbert, & Viau,
2007).
Such applications could lead to claims of discrimina-
tion in hiring or job placement. Concerns regarding
potential discrimination, particularly in employment
and insurance, have led to legislative and policy efforts
to prohibit or limit such use of biological data. In the
United States, the Genetic Nondiscrimination Act of 2008
prohibits discrimination based on ‘‘genetic information’’
(including RNA or chromosomal changes), but does
not encompass any other potential biomarkers. Several
European countries have also enacted specific legislation
prohibiting genetic discrimination in specific circum-
stances, including Belgium, Austria, Denmark, France,
Germany, Lithuania, Norway, Portugal, and Sweden
(Otlowski, Taylor, & Bombard, 2012). There are two bills
currently pending in Canada to amend the Canadian
Human Rights Act to prohibit discrimination based on
genetic data. International efforts to address risks for
discrimination include the United Nations Educational,
Scientific, and Cultural Organization (UNESCO) Uni-
versal Declaration on the Human Genome and Human
Rights (1997) and International Declaration on Human
Data (2003), which prohibit genetic discrimination. The
Council of Europe’s influential European Convention on
Human Rights and Biomedicine (1997), known as the
Oviedo Convention), prohibits discrimination based on
genetic heritage, and the European Union’s Charter of
Fundamental Rights (2000) includes genetic data in its
nondiscrimination clause. Other efforts to reduce risks
of genetic discrimination include the implementation of
guidelines and code of practice, voluntary moratoria, and
the development of independent bodies with monitoring
or policy advocacy agendas (Otlowski et al., 2012). These
efforts are all specific to discrimination based on genetic
data, but the potential for discrimination based on non-
genomic biomarkers for PTSD (or other medical illnesses
or conditions) remains to be addressed.
Shouldanyqualifiedapplicanthavetherighttoserve,or
do risk factors for PTSD constitute a legitimate cause for
rejection? It is not clear whether such biomarkers would
have a similar status to personality characteristics, for
example, that associate with increased risk or poor per-
formance and which are currently deemed relevant for
employmentinhigh-riskjobs,suchaslawenforcement.On
the other hand, the identification of pre-exposure risk
markersmayalsoraiselegalliabilityissuesforanemployer
who places a high-risk employee in an environment where
trauma exposure is likely. For example, British combat
veterans brought one of the largest personal injury suits
in UK history against the United Kingdom’s Ministry
of Defense for negligence in failing to ‘‘screen out vulner-
able individuals’’ and to ‘‘debrief them properly,’’ among
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tors may be used proactively to target service members
for resilience training pre-deployment, or for ‘‘watchful
waiting’’ following trauma exposure, but the potentially
negative consequences of identifying service members
with a PTSD risk factor must be considered. How might
the identification of some as higher risk for PTSD affect
unit cohesion and trust among soldiers? The potential for
stigma, with its myriad consequences, is high. Enhanced
monitoring of those at risk following trauma exposure
also raises the specter of iatrogenic effects. For those who
develop PTSD and are found to have pre-existing bio-
logical risk factors, might this be used to denyor minimize
claims for compensation and benefits? A biomarker of
pre-traumatic risk might be taken as a sign of weakness
that invalidates the profound impact of combat and the
suffering and impairment associated with PTSD. Baum
and Savulescu (2013) argue that once biomarkers of risk
havebeen identified, themoral landscape changes, andthe
ethical burden shifts so that not using biological informa-
tion requires justification. How to use that information,
however, remains to be established.
Furthermore, it is increasingly clear that ‘‘risk’’ is not a
static category in PTSD, when risk for disorder changes
with multiple deployments or exposures, for example
(Yehuda, Neylan, et al., 2013). Markers of ‘‘resilience’’
alsodo notnecessarily permanentlyprotectagainst illness.
This means that tests for risk might need to be adminis-
tered periodically to those chronically exposed to trau-
maticstressorstoaccountfor‘‘wearandtear.’’Individuals
who show biomarkers of resilience, or who lack the risk
biomarkers, may experience a false sense of security or
blame themselves shouldtheybecome symptomatic(Silver
& Sharp, 2006). The identification of dynamic biological
networksthat aresensitive toongoingperturbations inthe
environmentmayelucidate howbiologychanges over time
and in response to life events to increase (or decrease) risk
of symptoms. To use a risk marker as a screening tool may
overestimate and overvalue its influence and discount the
potential for individual resilience. It may be that risk
markers are most valuable in the study of PTSD patho-
physiology in support of development of new preventative
and treatment interventions.
The use of biomarkers of recovery and treatment
response also raises social, ethical and legal issues. What
might the implications be for compensation and benefits
if an individual shows normalization in biological indica-
tors of PTSD following treatment but continues to report
distressing or impairing symptoms? For example, a recent
fMRI studyof psychotherapy for PTSD inveterans found
improvement in cerebral function following treatment
while PTSD symptom reduction as assessed by the
Clinician Administered PTSD Scale for DSM-IV (CAPS)
was modest (Roy et al., 2010). Conversely, how might it
affect a service member’s job posting, chance of promo-
tion, or sense of self if he or she reports improvement but
continues to evidence biomarkers of disorder? Prognostic
indicatorsmayhelpguidetreatmentchoice,butmightthey
also become a self-fulfilling prophesy for those with bio-
markers of treatment resistance? As the pursuit of PTSD
biomarkers continues, a parallel conversation regarding
ethical and legal implications is needed.
Conclusions
It is tempting to think that the application of biological
information to clinical and employment-related decision-
making will be a straightforward good, and there are
clearlymanypotentiallybeneficialapplicationsofputative
biomarkers of PTSD. Biological markers with sufficient
specificity may assist in validating PTSD diagnosis,
assessing risk for PTSD, and documenting trauma ex-
posure. Routinely incorporating biological measures into
clinicalresearchcouldalsoprovideinvaluableinformation
on the degree of recovery necessary to produce significant
and substantial change in underlying pathophysiology of
the disorder. Such a change might be a more accurate
indicator of recovery and associate with reduced chance
of recrudescence. Additionally, treatment outcome studies
that incorporate genetic, neuroendocrine, epigenetic, and
neurobiological markers may generate predictors of treat-
ment response, recommendations for treatment matching,
and new insights that may inform the development of
more refined psychological and pharmacologic interven-
tions for the successful treatment of PTSD.
TheoptimismovertheutilityofPTSDbiomarkersmust
be tempered by consideration of the potential ethical,
social, clinical and legal implications of their applications.
The potential implications and applications of biomarkers
of disease have been more widely discussed in other areas
of medicine where biological markers have been more
robustly established, such as Alzheimer’s disease (e.g.,
Gauthier, Leuzy, Racine, & Rosa-Neto, 2013; Illes, Rosen,
Greicius,&Racine,2007;Prvulovic&Hampel,2011;Slats
etal., 2010),butsuchdiscussion hasbeen lackingin PTSD
research. As the field advances, interdisciplinary perspec-
tives from clinicians, bioethicists and legal scholars should
be solicited. The opportunities for biomarkers to improve
clinical care and treatment are exciting. They also invite
responsible reflection to ensure the greatest good with the
least harm.
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